We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+6.51%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$904M
AUM Growth
+$341M
Cap. Flow
+$316M
Cap. Flow %
34.95%
Top 10 Hldgs %
51.85%
Holding
63
New
24
Increased
11
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$48.9M
2
UTHR icon
United Therapeutics
UTHR
+$25.4M
3
BIIB icon
Biogen
BIIB
+$24.9M
4
ARVN icon
Arvinas
ARVN
+$24.3M
5
JBIO
Jade Biosciences
JBIO
+$19.9M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$35.5M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$27.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$21.8M
4
BNTX icon
BioNTech
BNTX
+$18.2M
5
ETNB
89bio
ETNB
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB.WS
51
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$18K ﹤0.01%
66,666
– –
ALLK
52
DELISTED
Allakos
ALLK
– –
-2,900,000
Closed -$660K
BNTX icon
53
BioNTech
BNTX
$23.2B
– –
-200,000
Closed -$18.2M
CMPS
54
Compass Pathways
CMPS
$1.53B
– –
-2,000,000
Closed -$5.72M
CRNX icon
55
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-350,000
Closed -$11.7M
ETNB
56
DELISTED
89bio
ETNB
– –
-2,500,000
Closed -$18.2M
GERN icon
57
Geron
GERN
$949M
– –
-8,000,000
Closed -$12.7M
NUVL
58
DELISTED
Nuvalent
NUVL
– –
-500,000
Closed -$35.5M
SLDB icon
59
Solid Biosciences
SLDB
$789M
– –
-100,000
Closed -$370K
SLNO
60
DELISTED
Soleno Therapeutics
SLNO
– –
-250,000
Closed -$17.9M
TEVA icon
61
Teva Pharmaceuticals
TEVA
$36.2B
– –
-1,700,000
Closed -$27.4M
XENE icon
62
Xenon Pharmaceuticals
XENE
$6.34B
– –
-650,000
Closed -$21.8M
ARTV
63
Artiva Biotherapeutics
ARTV
$498M
– –
-145,089
Closed -$435K
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2025 Portfolio in Review

As of Q2 2025, Logos Global Management held 63 positions worth $904M, up 61% from $563M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Logos Global Management deployed $316M of net new capital in Q2 2025, opening 24 new positions and adding to 11 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 450,000 shares worth $47.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $17.1M trimmed.

  • Logos Global Management's largest Q2 2025 buy was Jazz Pharmaceuticals: 450,000 shares worth $47.8M.
  • Logos Global Management added most to Jade Biosciences in Q2 2025, an estimated $19.9M increase.
  • Logos Global Management's biggest Q2 2025 reduction was Janux Therapeutics, cutting an estimated $17.1M.
  • Logos Global Management fully exited Nuvalent in Q2 2025, selling an estimated $35.5M.
  • Logos Global Management's ten largest holdings make up 52% of its $904M portfolio in Q2 2025.
  • Logos Global Management opened 24 new positions and closed 12 in Q2 2025.
  • Logos Global Management's portfolio value rose 61% quarter-over-quarter to $904M.

Based on Logos Global Management's 13F filing for Q2 2025, filed 14 Aug 2025.